Nurix (NRIX) CSO Gwenn Hansen Sells Shares

What Happened

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), had restricted stock units (RSUs) convert into common stock on July 30, 2026 (10,180 shares total: 3,750 + 2,858 + 3,572). A portion of the shares—3,847—were sold in an open-market "sell-to-cover" transaction at a weighted average price of $23.38 for total proceeds of $89,954. The RSU conversions are reported as acquisitions at $0.00 per share (reflecting RSU settlement).

Key Details

• Transaction date: July 30, 2026.
• Acquired via derivative conversion: 10,180 shares at $0.00 (RSU settlement).
• Sold in open market (sell-to-cover): 3,847 shares at a weighted average $23.38; proceeds $89,954. Reported sale price range: $23.00–$23.90.
• Shares owned after transaction: not specified in the filing.
• Footnotes: sale was a mandatory "sell to cover" to satisfy tax withholding on vested RSUs (not a discretionary trade). RSUs convert 1:1 to common shares and vest quarterly (1/12 each quarter) over three years per the award schedules noted in the filing.
• Filing timing: Reported on July 30, 2026 (same-day report), with no late filing noted.

Context

• This was not a cash purchase — Hansen received shares from vested RSUs (derivative conversion) and sold only enough shares to cover tax withholding (common practice for RSU settlements). Such sell-to-cover transactions are routine and do not necessarily signal a change in insider sentiment.